Medicxi, RA Capital join $30M round for Dutch biotech's late-stage transplantation med
Bringing Medicxi and RA Capital Management into the fold, Xenikos has clinched $30 million in Series B funding to push its transplantation med through the last big research lap before approaching regulators’ doors.
Nijmegen, the Netherlands-based Xenikos is developing a therapy for steroid-resistant acute graft-versus-host disease called T-Guard, which helps restore balance in the immune system following hematopoietic stem cell transplantation. With the new funds, the biotech plans to conduct Phase III trials in both the US and EU — where T-Guard has been designated an orphan drug — as well as invest in commercial scale production.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.